Application: Using The Chemyx Fusion 4000 Syringe Pump In Delivery of mRNA Vaccines – MIT Research

Read The Full Article here: Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation

LNP synthesis. An organic phase was prepared by solubilizing with ethanol a mixture of the synthesized cationic lipid, DOPE (Avanti), cholesterol (Avanti) and C14-PEG 2000 (Avanti) at a predetermined molar ratio. The aqueous phase was prepared in 10 mM citrate buffer (pH 3.0, Fisher) with mLuc (firefly mLuc, Translate), antigen mRNA or nontranslating Cy5-labeled FLuc mRNA (TriLink BioTechnologies). All mRNAs were stored at −80 °C, and were allowed to thaw on ice before use. The ethanol and aqueous phases were mixed at a 3:1 ratio and a lipid/mRNA weight ratio of 10:1 in a microfluidic chip device using syringe pumps (Fusion 4000 Chemyx Syringe Pump) as previously described39. Resultant LNPs were dialyzed against 1X PBS in a 20,000 MWCO cassette (Fisher) at 4 °C for 1 h and were stored at 4 °C before injection. For high-throughput screening, the LNPs were prepared in a 96-well plate by directly adding ethanol phase to aqueous phase. For in vitro screening, LNPs were directly incubated with cells without further dialysis. For in vivo batch analysis screening, LNPs in each classification group (for batch analysis) were mixed and dialyzed against 1X PBS before injection into mice.

Article by:
Dr. Chandrabali Bhattacharya
JDRF Postdoctoral Fellow
Anderson and Langer Lab
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology

Have any questions or comments about this article? Fill out the form below and we'll get back to you as soon as possible!

Privacy & Terms

By choosing "I agree" below you agree to Chemyx Inc Terms of Service. You Also agree to our Privacy Policy, which describes how we process your information.